483 results about "Quinazoline derivatives" patented technology

This invention provides the treatment of viral infections with a 4,6-disubstituted or 2,4,6-trisubstituted quinazoline derivative represented by the structural formula [(I)] wherein: R₂ is selected from the group consisting of hydrogen, NR′R″ and C_1-7 alkyl; —A is selected from the group consisting of a bond, O, S(O)_n, C_1-7 alkylene, C_2-7 alkenylene and C_2-7 alkynylene; R₄ is selected from the group consisting of C_1-7 alkyl, C_2-7 alkenyl, C_3-10cycloalkyl, C_3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted alkyl and cycloalkyl-alkyl; —Y is selected from the group consisting of a single bond, C_1-7 alkylene, C_2-7 alkenylene, and C_2-7 alkynylene; n is 0, 1 or 2; and R₆ is selected from the group consisting of halogen, heteroaryl and aryl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-Λ/-oxide, a solvate or a pro-drug thereof.

The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups R_a, R_b, R_c and R_d have the meanings given in the claims, as well as sulphonyl derivatives of formula (XIII) and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.

The invention relates to a 4-aromatic aminoquinazoline compounds with general formula of (I) or a receivable salt pharmaceutically and the application in preparing the drugs for treating the tumour. Wherein, R1, R2 are hydrogen, halogen, nitryl, amino, alkyl of C1-6, alkylamino of C1-6 or alkoxy of C1-6, or the group replaced by the alkylamino on the terminal of the alkyl of C1-6, alkylamino and alkoxy; X is N,O or S; Ar is aromatic ring or heteroaromatic groups replaced by the ester of C5 to C8. The invention can inhibit the increase of the tumour cell obviously and has obvious inhibited effect on the tyrosine kinase of the cell, and has activity equal to that of the positive drugs Gefitinib and Erlotinib and even exceeds the positive control.

The invention relates to quinazoline derivatives having a general formula (I), and mixture of their optically active body or racemic body, and diastereoisomer, their pharmaceutically acceptable salts, hydrate or solvate, wherein R1, R2, A, X and Q1 are defined in the specification. The derivatives can be used for preparing protein tyrosine coyness inhibitor, and for preparing medicament for treating and/or preventing cancer and other hyperplasia diseases.

An image pickup device comprises an organic photoelectric conversion film sandwiched between at least two electrodes, wherein the organic photoelectric conversion file comprises a specific quinacridone derivative or a specific quinazoline derivative.

Methods for preparing compounds having the following structure (I):

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R¹, R^2a, R^2b, R^3a, R^3b, R^4a, R^4b and R^4c, are as defined herein are provided. Related compounds and methods for making the same are also provided.

The invention discloses a 2-aryl quinazoline or 2-heterocyclic aryl quinazoline derivative and a preparation method thereof. The structural formula of the product is shown in a formula (i), wherein Ar represents aryl, substituted aryl, heterocyclic aryl or substituted heterocyclic aryl. The preparation method of the 2-aryl quinazoline or 2-heterocyclic aryl quinazoline derivative comprises the following steps of: reacting aromatic formaldehyde or heterocyclic aromatic formaldehyde with ortho-amino toluamide at high temperature to obtain a 2-aryl quinazoline-4(3H)-ketone derivative or a 2-heterocyclic aryl quinazoline-4(3H)-ketone derivative; subsequently reducing the 2-aryl quinazoline-4(3H)-ketone derivative or the 2-heterocyclic aryl quinazoline-4(3H)-ketone derivative into a 2-aryl-3,4-dihydro quinazoline derivative or a 2-heterocyclic aryl-3,4-dihydro quinazoline derivative by using an appropriate reducing agent; and finally synthesizing the 2-aryl quinazoline or 2-heterocyclic aryl quinazoline derivative by using an oxidizing agent in an oxidation mode. Compared with the conventional synthesis method, the preparation method has the advantages of easy and available raw material, simple synthesis method, temperate reaction condition, high yield and the like, is easy to purify, and is a synthesis method applicable to industrial production.

The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE.

The invention discloses a quinazoline derivative and a pharmaceutically acceptable salt thereof showed in a formula I, or their enantiomer, diastereoisomer, tautomer, racemate, solvate, metabolic precursor or prodrug. The invention also discloses a preparation method, an intermediate, a composition and an application. The quinazoline derivative has good antineoplastic activity.

An object of the present invention is to provide an antipruritic agent having a novel action mechanism.

The present invention provides an antipruritic agent comprising a compound represented by the following general formula (1):

wherein R¹ represents a hydrogen atom or alkyl; the ring Q represents a cyclohexylene group or a phenylene group; A¹ and A² represent a single bond or an alkylene group; E represents —NHCO—; A³ represents a single bond or a divalent saturated or unsaturated aliphatic hydrocarbon group; R³ represents a non-cyclic aliphatic hydrocarbon group; and R⁴ and R⁵ are the same or different and each represents a hydrogen atom or alkyl, or a pharmaceutically acceptable salt thereof as an active ingredient.

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

The present invention relates to quinazoline derivatives of formula I:

wherein X, Y, Z, R₁, R₂, R₃, and R₄ are as defined herein. The invention also relates to a method of preparing these compounds, and use of these compounds for inhibiting tumor growth.

The invention discloses a phosphorescence iridium complex by taking a quinazoline derivative as a ligand and an organic electroluminescent device thereof. The structure of the phosphorescence iridium complex disclosed by the invention is represented by the formula (I) or the formula (II) described in the specification, wherein Ar represents aryl, substituted aryl, heterocyclic aryl and substituted heterocyclic aryl; R can be one of a halogen atom, alkyl, substituted alkyl, alkoxy, aryloxy, alkyl sulphanyl, aryl sulphanyl, aromatic amino, fatty amino and heterocyclic substituent; L^Y can be one of N^COOH, N^OH, beta-diketone, N^NH and the like; N^N can be bipyridyl, biquinolyl, phenanthroline and derivatives thereof and the like; and Z can be a hexafluorophosphoric acid radical, a perchloric acid radical and the like. A light-emitting layer of the electroluminescent device disclosed by the invention is prepared by adopting a spin coating and film-preparing method under a specified condition, has the advantages of being low in cost, simple for operation and steady in chemical property, and is beneficial to preparing large-screen electroluminescent devices.